ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

ClinicalTrials.gov ID: NCT05696717

Public ClinicalTrials.gov record NCT05696717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy

Study identification

NCT ID
NCT05696717
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Theravance Biopharma
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • Ampreloxetine Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 26, 2023
Primary completion
Dec 31, 2025
Completion
Dec 31, 2027
Last update posted
Sep 4, 2025

2023 – 2028

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Movement Disorders Center of Arizona Scottsdale Arizona 85258
The Parkinson's and Movement Disorder Institute Fountain Valley California 92708
UC San Diego Movement Disorder Center La Jolla California 92037
David Geffen School of Medicine at UCLA Los Angeles California 90095
Stanford Neuroscience Health Center Palo Alto California 94304
Medstar Georgetown University Hospital Washington D.C. District of Columbia 20007
Parkinson's Disease And Movement Disorders Center of Boca Raton Boca Raton Florida 33486
SFM Clinical Research, LLC Boca Raton Florida 33487
Aqualane Clinical Research Naples Florida 34105
Neurostudies, Inc Port Charlotte Florida 33952
University of South Florida Ataxia Research Center Tampa Florida 33612
Emory University Atlanta Georgia 30329
Hawaii Pacific Neuroscience Honolulu Hawaii 96817
Rush University Medical Center Chicago Illinois 60612
Northshore University Health System Glenview Illinois 60026-1339
University of Kansas Medical Center Research Institute, Inc. Kansas City Kansas 66160
Brigham and Women's Hospital (Neuromuscular Division) Boston Massachusetts 02115
Massachusetts Chan Medical School Worcester Massachusetts 01655
Quest Research Institute Farmington Hills Michigan 48334
NYU Langone Health NYU Dysautonomia Center New York New York 10016
The Neurological Institute at Columbia University Medical Center New York New York 10032
University of Cincinnati Medical Center Cincinnati Ohio 45219
Vanderbilt University Medical Center Nashville Tennessee 37232
University of Texas Southwestern Medical Center Dallas Texas 75390
Baylor College of Medicine Houston Texas 77030
Movement Disorders and Autonomic Disorders Clinic; University of Utah Salt Lake City Utah 84108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05696717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 4, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05696717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →